Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| [C14]-LY2784544 | EXPERIMENTAL | Single 30 mg oral dose containing 100 micro curies of LY2784544 |
| Name | Type | Description |
|---|---|---|
| Drug | RADIATION | Single 30 mg oral dose containing 100 micro curies of LY2784544 |
Inclusion Criteria: * Overtly healthy males as determined by medical history and physical examination * Will either be sterile or, if sexually active, agree to use a reliable method of birth control from the day before dosing until 3 months after the end of the study * Have a body mass index (BM...
Drug is an investigational therapy being studied in healthy male volunteers. It is currently in Phase 1 clinical development, with a completed trial that enrolled 8 participants in the United States. The drug is not approved for any indication and remains under investigation.
Drug is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational drug, which is currently in Phase 1 development.
Drug is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 8 healthy male volunteers in the United States. The drug is investigational and has not been approved by regulatory authorities.
Drug has one completed clinical trial, identified as NCT01577355, titled "A Study of LY2784544 in Healthy Male Subjects." This Phase 1 study enrolled 8 healthy male volunteers aged 18 years and older in the United States.
Drug is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy volunteers is part of early-stage research, and the drug has not received marketing approval.